ArticleScientific reports2026
Perillyl alcohol attenuates hypoxia induced right ventricular dysfunction and remodeling by balancing the renin angiotensin aldosterone system in rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypoxia induced-pulmonary hypertension (HPH) is a life-threatening cardiovascular disorder prevalent in high-altitude regions. Right ventricular (RV) function and RV—pulmonary arterial (RV—PA) coupling are key to patient prognosis. Perillyl alcohol (POH), a natural compound, holds promise for managing pulmonary arterial hypertension (PAH). This study established HPH rat models via hypobaric chamber simulation (5000 m altitude) to explore the impact of POH on RV structure and function. Using a multi-modal approach, we employed echocardiography to assess RV function and RV-PA coupling. HE and Masson’s trichrome staining for tissue morphology and fibrosis. Immunohistochemistry, immunofluorescence, and western blotting to quantify collagen I/III and α-SMA. MDA, GSH, SOD, GSH-PX, IL-6 and TNF-α levels were measured using their respective commercial kits. ELISA/western blotting to analyze the ACE-Ang II-AT1R and ACE2-Ang (1–7)-MAS axes. Results showed that POH significantly restored RV function and RV-PA coupling, outperforming sildenafil in reducing RV structural changes (RVID-D, RVID-S, RVFT-D, RVFT-S). It normalized hypoxia-elevated hematological parameters (HCT, HGB, RBC), alleviated cardiomyocyte hypertrophy, fibrosis and inflammatory, and reversed RV remodeling. Mechanistically, POH exerted antioxidant effects and modulated the renin–angiotensin–aldosterone system (RAAS), decreasing ACE, Ang II, and AT1R levels while increasing ACE2, Ang (1–7), and MAS expression. In conclusion, POH improves RV function, preserves RV-PA coupling, and reduces RV systolic pressure, indicating its potential as an effective therapy for PAH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.